IndoG6PD · Phase 1Tribal Odisha G6PD Orissa · 97.9%Primaquine/tafenoquine safety layer

India's highest-frequency tribal genetic drug-safety risk.

G6PD Orissa (c.131C>G, p.Ser44Cys) is found in ~97.9% of G6PD-deficient individuals screened in tribal Odisha PVTG populations. WHO Class II severe deficiency. Primaquine and tafenoquine — the only radical-cure drugs for P. vivax malaria — carry high acute hemolysis risk in these patients. No existing tool scores Indian-specific G6PD variants for structural severity. This is Phase 1.

Phase 1 today — curated Indian G6PD variant knowledge + WHO class alignment + primaquine/tafenoquine guidance per severity tier + regional epidemiology overlay. Phase 1b plugs into the same API contract — local ESM1b masked-marginal scoring per PRD §5.2 (fair-esm + esm1b_t33_650M_UR50S weights + UniProt P11413 canonical sequence + Legion 5 RTX 3060 6GB VRAM adequate for fp16 inference). ESM scores here are WHO-class-derived placeholders per PRD §11 no-fabrication policy.

PRD §11 NO-FABRICATION POLICY · VARIANTS MARKED verification_required PENDING PMID CONFIRMATION
ESM scores displayed here are WHO-class-derived placeholders — replaced with live esm1b_t33_650M_UR50S masked-marginal output when Phase 1b (local GPU inference) lands. Frequencies with verification_required=true need PMID confirmation against primary Indian tribal screening literature before customer-facing use.

The IndoG6PD phase stack

Same-API-contract expansion. Phase 1b, 2, 3 all plug into POST /g6pd/check — adopters integrating today won't need to rewrite when live inference or hemoglobinopathy modules land.

Phase 1 · live
Curated variant knowledge layer
Indian G6PD variants (Orissa dominant) + WHO class alignment + primaquine/tafenoquine guidance + regional epidemiology. NO fabricated data (PRD §11). Placeholder ESM scores.
Phase 1b · local GPU
Live ESM1b masked-marginal scoring
fair-esm + esm1b_t33_650M_UR50S weights + UniProt P11413 canonical sequence. Legion 5 RTX 3060 6GB VRAM adequate. Replaces placeholder scores; runs off-cloud.
Phase 2 · not yet
Sickle cell + thalassemia co-inheritance
HbS · HbD Punjab · β-thalassemia over HBB (P68871). Same masked-marginal pipeline. Combined risk output for co-inherited hemoglobinopathies.
Phase 3 · frontier
Epigenetics one-carbon bridge
MTHFR · MTRR · MTR · CBS variant scoring + methylation correlation. Requires wet-lab collaboration for methylation data — no fabricated correlations.
Computational structural prediction. Not a substitute for laboratory G6PD enzyme activity testing or clinical judgment. Decision support only.